Summit Therapeutics Inc.
IPO- Headquarters
- Miami, Florida
- Employees
- 51–200
- Founded
- 2003
- Business Model
- B2B
- Website
- smmttx.com
- Total Funding
- $500.0M
- Last Round
- $500.0M Corporate RoundOct 2025
- Rounds
- 3
- Type
- Public
About
Summit Therapeutics is a biopharmaceutical oncology company focused on discovering and commercializing patient-friendly cancer therapies. Its lead investigational therapy, ivonescimab, is a novel bispecific antibody combining PD-1 and VEGF blockade, currently in multiple Phase 3 clinical trials for non-small cell lung cancer and colorectal cancer. The company licensed ivonescimab from Akeso Inc. in 2023 for the US, Canada, Europe, Japan, and other territories.
Tech & App Stack
Tech & App Stack is available on paid plans
Upgrade to Silver or higher to reveal the full technology and app stack for any company.
View pricingSign up to view funding chart
Create a free account to see funding visualizations and detailed round data.
Create Free AccountFunding History
Investors
Sign up to view investors
Create a free account to see which investors have funded this company.
Create Free AccountSimilar Companies
BridgeBio Pharma is a clinical-stage biopharmaceutical company developing therapies for genetic d...
Clinical-stage biopharmaceutical company developing FcRn inhibitor therapies for IgG-mediated aut...
Commercial-stage oncology company pioneering antibody drug conjugate therapies for cancer treatment.
Global clinical-stage biopharmaceutical company pursuing novel drug development platforms for rar...
Research-based development stage biopharmaceutical company that discovers and develops innovative...
Clinical-stage biopharmaceutical company developing T cell receptor-based adoptive cell therapies...